Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update
Sacituzumab govitecan increases PFS for HR+/HER2‐ advanced breast cancer patients
TROPiCS-02: sacituzumab govitecan in HR+/HER- breast cancer
#ESMO22 Highlights on sacituzumab govitecan in HR+/HER2- metastatic breast cancer: TROPiCS-02
Sacituzumab govitecan effective for HR+ metastatic breast cancer regardless of Trop-2 status
TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer | Hope Rugo
Study of SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer
TROPiCS-02: sacituzumab govetican improves PFS versus physicians choice for HR+/HER2- mBC
The ASCENT of sacituzumab govitecan in metastatic TNBC | Aditya Bardia
Sacituzumab govitecan for treatment-refractory metastatic breast cancer
Final OS analysis of sacituzumab govitecan in TROPiCS-02
ASCENT: sacituzumab govitecan biomarker analysis
2nd interim analysis of OS from TROPiCS-02: SG in HR+/HER2- breast cancer
Antibody Drug Conjugates in Metastatic Breast Cancer | Anthony Elias, MD | ESMO22 Colorado
Top 5 Breast/GYN Cancer Advances in 2023: #2 Metastatic Breast Cancer Drug Approvals
Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer
Effectiveness of TDXD vs. Sacituzumab for ER+ Breast Cancer | Jane Meisel, MD | ASCO22 Updates
Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancer
